Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide
    Growth Hormone / IGF-1 AxisFDA Approved

    Tesamorelin Dosage Guide: Protocols, Calculator & Safety

    Everything you need to know about Tesamorelin dosing: protocols and safety.

    Dose Range

    1,000–2,000 mcg (1–2 mg) daily

    Frequency

    Once daily subcutaneous injection

    Cycle Length

    12-26 weeks in clinical trials; ongoing use common

    Half-Life

    8 to 11 minutes in healthy subjects (EGRIFTA SV and EGRIFTA WR labels)

    Administration Routes

    subcutaneous

    Quick Reconstitution Calculator

    Calculate syringe units instantly

    Syringe Draw

    10.0 units

    2500 mcg/ml · 0.100 ml draw

    Full Tool

    For laboratory research use only. This tool performs reconstitution math (concentration and syringe-unit conversion) and is not dosing guidance for humans or animals.

    Dosing Protocols

    Beginner

    The goal is to match the FDA-approved protocol used in the pivotal HIV lipodystrophy trials.

    Standard tesamorelin protocol: weeks 1-12

    • Inject 2 mg subcutaneously, once daily.
    • Inject pre-bed and fasted (≥2 hours post-meal). A pre-bed injection amplifies the nocturnal GH burst, the body's largest physiologic pulse and the point where tesamorelin's mechanism is most efficient.
    • Use abdominal subcutaneous fat at least 2 inches from the navel, and rotate L/R each day.
    • Use a 29-31G × 1/2" insulin syringe.
    • Reconstitute a 2 mg vial with 2.1 mL 0.9% sterile sodium chloride (per the package insert), or with 1 mL bacteriostatic water for off-label use. The FDA label treats reconstituted solution as single-use, but in practice it is typically stable for 5-7 days refrigerated.
    • Refrigerate the unreconstituted vial. Use reconstituted solution immediately (per label) or within 5 days refrigerated (off-label).

    What to expect in weeks 1-12

    • In weeks 1-2, expect mild redness or itch at the injection site and possibly mild head-heaviness after injecting; sleep may deepen.
    • In weeks 2-4, mild peripheral edema may appear, joint stiffness sets in and IGF-1 is rising.
    • By weeks 4-8, IGF-1 typically reaches steady state. VAT is starting to fall, though not yet visibly.
    • In weeks 8-12, waist circumference reduction becomes measurable (~1-2 cm is typical), with subjective improvement in sleep quality, recovery and body composition.
    • Over the full protocol (26 weeks, per the Phase 3 trial), VAT falls ~15-18% from baseline, which DEXA or CT can quantify.

    Required monitoring

    • At baseline, check fasting glucose, IGF-1, HbA1c, CMP, lipid panel, PSA (men >40) and a thyroid panel.
    • At week 4, check IGF-1 and fasting glucose.
    • At week 12, run the full panel.

    When to dose-reduce or stop

    • If IGF-1 exceeds the age-adjusted ULN (typically >250 ng/mL in adults 30-50), reduce to 1 mg daily.
    • If HbA1c rises >0.3 points, investigate glucose management.
    • For persistent peripheral edema or carpal tunnel symptoms, reduce the dose or discontinue.
    • Any new palpable mass, unexplained weight loss or red-flag symptom calls for a cancer workup before continuing.
    Standard

    This stage combines tesamorelin with a ghrelin-receptor agonist for a larger GH pulse amplitude, which is the mechanistic argument for the "tesa + ipa" stack.

    Tesamorelin + Ipamorelin: 12-24 weeks

    • Take tesamorelin 2 mg SC once daily, pre-bed and fasted.
    • Add ipamorelin 200 mcg SC at the same injection, drawn into the same syringe.
    • The rationale: tesamorelin activates the GHRHR pathway (Gs / cAMP / PKA) and ipamorelin activates GHS-R1a (Gq/11 / PLC / IP3 / Ca2+). The two pathways converge on pituitary somatotrophs through distinct second messengers and produce a 3-5x larger GH pulse than either agent alone ([Bowers et al., 1991]). It is the most potent GHS configuration short of direct recombinant GH.

    Why tesamorelin + ipamorelin over MOD-GRF 1-29 + ipamorelin

    • Tesamorelin has stronger and more durable visceral-fat effects (~18% VAT reduction at 26 weeks, clinically proven).
    • Its GHRHR receptor occupancy is longer (30-50 min against 30 min for MOD-GRF), which gives the GH pulse a small extra boost.
    • FDA-approved, regulatory-grade sourcing is available, whereas MOD-GRF is research-grade.
    • Higher cost is the main trade-off.

    Timing optimization

    • Dose pre-bed, 2+ hours post-meal, to use the nocturnal GH burst.
    • In body-composition-focused protocols, some users add a morning fasted dose of ipamorelin 200 mcg SC, with no tesamorelin in the AM. Tesamorelin beyond 2 mg/day is not recommended, because the dose-response plateaus.

    Cycling

    • 12 weeks on / 4 weeks off is the conservative approach.
    • A 26-week continuous protocol (as in the FDA pivotal trial) is appropriate for established visceral adiposity, and extension studies confirm safety to 52 weeks.
    • Off-cycle IGF-1 should return toward baseline within 4-6 weeks. Persistent elevation suggests a need for monitoring before restarting.

    Bloodwork on the stack

    • At baseline, check fasting glucose, IGF-1, HbA1c, insulin, a comprehensive metabolic panel, lipid panel, PSA (men >40) and thyroid, plus DEXA or CT for a VAT baseline.
    • At week 4-6, check fasting glucose, IGF-1 and insulin.
    • At week 12, run the full panel and repeat the body composition measurement.
    • At the end of the cycle, run the full panel.
    Advanced

    This protocol aims for the most visceral-fat reduction and body composition change possible within intensive metabolic therapy, and it is meant for experienced users with full lab monitoring.

    Tesamorelin + Ipamorelin + MOD-GRF 1-29 pulsed: 16-24 weeks

    For maximal GH pulse density while staying within the physiologic envelope:

    • Tesamorelin 2 mg SC pre-bed plus ipamorelin 200 mcg in the same injection (the primary nocturnal pulse)
    • MOD-GRF 1-29 100 mcg plus ipamorelin 200 mcg SC in the morning fasted window (the secondary morning pulse)
    • That gives two discrete GH pulses per day, one driven by tesamorelin's longer receptor occupancy and one by the shorter pharmacokinetics of MOD-GRF 1-29.

    Combined with Semaglutide or Tirzepatide for recomposition

    The GHS stack preserves lean body mass during the caloric deficit induced by GLP-1 therapy, one of the most effective body recomposition strategies available in 2026:

    • GLP-1 therapy produces controlled weight loss, mostly fat mass, though 10-20% is typically lean mass.
    • Tesamorelin plus ipamorelin preserves lean mass through GH/IGF-1 and preferentially targets visceral fat.
    • The net result is greater lean mass retention and a stronger visceral-fat reduction than GLP-1 alone.

    For NAFLD / metabolic dysfunction-associated steatohepatitis (MASH)

    The Stanley 2014 trial supports off-label use of tesamorelin 2 mg/day for hepatic fat reduction. For documented NAFLD (imaging-confirmed hepatic fat fraction >5%):

    • Tesamorelin 2 mg daily for 6-12 months
    • Consider stacking NAD+ or NMN for hepatic mitochondrial support.
    • Monitor ALT, AST and GGT monthly, with MRI-PDFF or FibroScan at baseline and 6 months.

    Cycling considerations

    • 16-26 weeks on / 4-6 weeks off is the upper-end protocol.
    • Long-term use (>12 months continuous) requires quarterly bloodwork and an annual reassessment.
    • Tachyphylaxis is not well-characterized for tesamorelin, but pulsatile dosing makes it less concerning than with CJC-1295-DAC.

    Contraindications specific to advanced dosing

    • Any active malignancy (absolute)
    • History of pituitary or hypothalamic injury / surgery
    • Active diabetic retinopathy
    • Severe insulin resistance or uncontrolled T2DM
    • History of acromegaly
    • Known hypersensitivity to tesamorelin or mannitol (an excipient in the commercial formulation)

    Weight-Based Dosing

    FDA-approved dose is fixed at 2 mg/day regardless of body weight.

    Commonly Stacked With

    Tier 1: the canonical GHS stack

    Ipamorelin at 200 mcg per tesamorelin injection is the standard biohacking configuration. Through GHRH × ghrelin pathway synergy it produces GH pulses 3-5x larger than tesamorelin alone. Both go in the same injection, from the same syringe.

    Tier 2: metabolic and body recomposition stacks

    • Semaglutide or tirzepatide makes the recomposition stack. GLP-1 therapy produces the caloric deficit and fat loss, while tesamorelin plus ipamorelin preserves lean mass and preferentially targets visceral fat. Time the GH secretagogue pulse opposite the GLP-1 peak (tesamorelin pre-bed, GLP-1 in the morning or weekly).
    • With BPC-157 and TB-500, GH/IGF-1 elevation amplifies the collagen synthesis that BPC-157 and TB-500 enable. This is useful for tendon and ligament rehabilitation alongside body composition work.
    • NAD+ or NMN gives mitochondrial support during elevated protein synthesis and fat oxidation, and is particularly useful in off-label NAFLD protocols.
    • Testosterone (TRT) or enclomiphene can sit alongside it: the HPG and GH axes are independent, and optimizing both together is standard in integrative hormone clinics.

    Tier 3: advanced and specific-use stacks

    • MOD-GRF 1-29 / CJC-1295 fits tri-daily GH pulse protocols: tesamorelin pre-bed and MOD-GRF 1-29 in the morning fasted window, both with ipamorelin. The approach exploits the different pharmacokinetics of the two GHRH analogs.
    • Epithalon makes a longevity-framed stack that combines GH-axis amplification with pineal and telomere support.
    • GHK-Cu adds skin and connective tissue regeneration, with synergy from GH-axis anabolism.

    Do not stack

    • CJC-1295 with DAC is redundant at GHRHR and directly contradicts the pulsatile pharmacodynamics that make tesamorelin developable. CJC-1295-DAC's ~8-day half-life produces continuous GH elevation, so adding tesamorelin is mechanistically confused. Use one or the other.
    • Exogenous recombinant GH (somatropin) defeats the purpose. Somatropin replaces GH directly and bypasses the pituitary pulse mechanism that tesamorelin enables. Use one or the other.
    • Other GHRH analogs taken simultaneously are redundant: tesamorelin with sermorelin, or tesamorelin with MOD-GRF 1-29, in the same injection hits the same receptor. To stack multiple GHRH analogs correctly, use the "tri-daily with different GHRH analogs at different times" protocol rather than a shared injection.

    Practical notes

    • Tesamorelin and ipamorelin are chemically compatible and can be drawn into the same syringe and injected together.
    • In tri-daily protocols, keep ipamorelin plus MOD-GRF 1-29 separate from tesamorelin (different injections, different times).
    • For multi-peptide stacks that include BPC-157 / TB-500, use separate injection sites, since BPC-157 benefits from local delivery near the target tissue.

    Side Effects & Safety

    The FDA approval program gave tesamorelin a well-characterized side-effect profile, which is a significant advantage over non-approved GHRH analogs. **Common (>10% in Phase 3 trials)** - Injection site reactions (erythema, pruritus, pain at the site) are the most frequent adverse event (~22% of patients). They are usually mild and resolve with site rotation. - Arthralgia (joint aches), an IGF-1-mediated connective tissue effect, typically appears 4-8 weeks into dosing and then stabilizes. - Pain in the extremities relates to fluid shifts and peripheral tissue expansion. - Myalgia (mild muscle aches) also comes from IGF-1-mediated connective tissue changes. - Peripheral edema is dose-dependent, GH-mediated fluid retention; it is mild and usually resolves within weeks. **Uncommon (1-10%)** - Carpal tunnel symptoms come from fluid-shift-mediated peripheral compression and should prompt dose reduction or discontinuation. - Paresthesias (hand tingling) are an early sign of fluid retention. - Insulin resistance or raised fasting glucose can appear, since all GH-raising therapies impair glucose tolerance. The FDA label reports an intent-to-treat odds ratio of 3.3 (CI 1.4, 9.6) for reaching an HbA1c of 6.5% or more. - Rash and urticaria are hypersensitivity-spectrum reactions. **Important** - By week 26, 5% of treated patients had reached an HbA1c of 6.5% or more (hyperglycemia or new-onset diabetes), against 1% on placebo, so patients with diabetes or pre-diabetes need close monitoring. - Fluid retention is a concern with CHF: tesamorelin is contraindicated in patients with acute critical illness, heart failure or severe edema. - IGF-1 can rise above the reference range. Per the FDA label, 47% of patients had IGF-1 above 2 SDS and 36% above 3 SDS at 26 weeks, and 34% and 23% at 52 weeks. Tesamorelin carries no FDA boxed (black box) warning. **Contraindications per FDA label** - Disruption of the hypothalamic-pituitary axis (pituitary tumor removal, hypopituitarism, hypothalamic injury) - Active malignancy, as an absolute contraindication, because the GH/IGF-1 axis may accelerate tumor growth - Pregnancy - Pediatrics, where it has not been studied **What tesamorelin does not do** - It does not raise prolactin or cortisol, unlike GHRP-2/6 or hexarelin. - It does not cause the continuous GH elevation of CJC-1295-DAC. - Because the pulse pattern preserves physiologic regulation, it does not cause the acromegalic body-composition changes of chronic recombinant GH. - Unlike some older peptide injections, it does not cause injection-site lipodystrophy. **Monitoring requirements** Per the FDA label and standard clinical practice: - At baseline, check fasting glucose, IGF-1, HbA1c, a comprehensive metabolic panel and thyroid (TSH, free T4). - At weeks 4-8, check IGF-1 against the age-adjusted reference range, and reduce the dose or discontinue if it exceeds the ULN. - Quarterly on long-term therapy, check HbA1c, liver function, IGF-1 and fasting glucose. - Annually, reassess the need for continued therapy, since tesamorelin suppresses visceral fat without curing it. **Long-term safety framing** The Phase 3 and extension data cover ~2 years; beyond that, safety is extrapolated from the broader GH/IGF-1 literature. For adults on tesamorelin beyond 2 years, standard clinical practice is active surveillance for malignancy (general cancer screening appropriate for age and sex), periodic IGF-1 monitoring and glucose/HbA1c surveillance.

    Contraindications

    **Absolute contraindications (per FDA label)** - Disruption of the hypothalamic-pituitary axis (pituitary tumor or removal, hypopituitarism, hypothalamic injury) rules it out. Tesamorelin requires an intact pituitary to work and can potentially accelerate residual tumor growth. - In active malignancy the GH/IGF-1 axis may accelerate tumor growth. It is an absolute contraindication during active cancer treatment or within 5 years of complete remission. - Do not use it in pregnancy (category X). - GH elevation can worsen active proliferative or severe non-proliferative diabetic retinopathy. - Known hypersensitivity to tesamorelin or mannitol (an excipient in the commercial formulation) also excludes it. **Additional off-label biohacking contraindications** - Uncontrolled T2DM should be optimized before starting, because tesamorelin acutely impairs glucose tolerance. - Active diabetic retinopathy counts at any grade, even non-proliferative. - A history of acromegaly or pituitary adenoma is an absolute contraindication. - In severe heart failure (NYHA III-IV), fluid retention can precipitate decompensation. - Tesamorelin is not safe during severe acute illness (sepsis, post-surgical critical care), which mirrors the recombinant GH warnings on acute critical illness. **Relative contraindications (consult physician before use)** - Type 2 diabetes or pre-diabetes calls for monitoring; expect HbA1c to rise ~0.1-0.3 points. - In uncontrolled hypertension, fluid retention can exacerbate blood pressure. - With a history of carpal tunnel syndrome, fluid retention can reactivate symptoms. - In hypothyroidism, optimize thyroid status first, since thyroid status affects the GH axis. - Above age 70, efficacy data are limited, and safety data from HIV trials do not include most elderly populations. **Drug interactions** - Chronic systemic glucocorticoids suppress the GH axis and blunt tesamorelin's efficacy. - Insulin and oral hypoglycemics may require dose adjustments because of tesamorelin's effect on glucose tolerance. - Tesamorelin is not a CYP3A4 inhibitor or inducer, so interactions with CYP3A4 substrates are minimal. - Do not combine it with exogenous recombinant GH, which is redundant. - Do not use other GHRH analogs simultaneously at the same receptor. **Monitoring requirements** - At baseline, check fasting glucose, IGF-1, HbA1c, a complete metabolic panel, thyroid (TSH, free T4), PSA (men >40), CBC and a lipid panel. - At week 4-6, check IGF-1; the target is within the age-adjusted reference range, typically <250 ng/mL for adults 30-50. - Every 12 weeks on therapy, check IGF-1, HbA1c and fasting glucose. - Annually, run the full panel and reassess the need for continued therapy. **Discontinuation criteria** Stop tesamorelin and consult a clinician on any of these: - IGF-1 > age-adjusted upper limit - HbA1c rising >0.4 points within one cycle - Persistent peripheral edema or new carpal tunnel symptoms - Any new palpable mass, a changing mole or unexplained weight loss (cancer workup indicated) - Severe headache, visual changes (rule out pituitary pathology) - Signs of fluid overload or CHF decompensation

    Check interactions with the Interaction Checker →

    Additional Notes

    The standard therapeutic dose is 2 mg subcutaneous, once daily, pre-bed, fasted.

    It is the FDA-approved dose for HIV lipodystrophy and the dose used across all major clinical trials. Doses above 2 mg/day have been studied (up to 4 mg/day) and do not produce a proportional IGF-1 rise (the dose-response curve flattens), while the side-effect burden rises substantially, with more edema and arthralgia and a higher carpal tunnel risk.

    Dosing fasted is essential. Elevated insulin suppresses GH release through several mechanisms (increased somatostatin tone, reduced somatotroph cAMP sensitivity), and post-meal tesamorelin dosing can cut the GH pulse by 50-70%. All GHRH analogs share this fasted-state requirement.

    Dose conversions (2 mg vial + 2.1 mL sterile saline per FDA label)

    • Concentration: ~0.95 mg/mL
    • A 2 mg dose is 2.1 mL, the entire reconstituted vial, each day (per label).
    • Commercial Egrifta SV comes in pre-loaded single-use syringes.

    For compounded / research-use tesamorelin

    • Typical: 5 mg vial + 2.5 mL bacteriostatic water = 2 mg/mL
    • 2 mg dose = 1 mL = 100 units on a 1 mL insulin syringe
    • Alternative: 1 mg vial + 1 mL BAC water = 1 mg/mL, so a 2 mg dose = 2 mL (impractical; use 5 mg vials)

    Timing

    • Pre-bed (evening, 2+ hours post-meal) is the FDA-approved timing and the most physiologic, because it amplifies the largest endogenous GH pulse of the day.
    • Morning fasted dosing is not an alternative. The pre-bed dose uses the nocturnal GH architecture, and moving tesamorelin to the morning reduces efficacy.
    • Do not dose pre-workout: peri-exercise insulin and metabolic shifts blunt the response, and training's natural GH pulse does not benefit from superimposed tesamorelin.

    Interactions with nutrition

    • Carbohydrates and protein both elevate insulin and blunt the GH response, so the fasted state is required.
    • Caffeine is neutral and may enhance the response a little through a mild adrenergic effect.
    • Alcohol independently suppresses GH secretion; avoid it within 4 hours of dosing.

    Dose adjustments in specific populations

    • In renal impairment (eGFR <60), dose reduction is typically not required, but monitor.
    • In hepatic impairment, use with caution, since hepatic IGF-1 production may be impaired.
    • Above age 65, some clinicians start at 1 mg and titrate; age-related declines in GHRH sensitivity are modest but present.
    • In active T2DM, start at 1 mg with close glucose monitoring and escalate only if glucose control is maintained.

    The Reconstitution Tool handles any custom vial size or diluent volume calculation.

    Frequently Asked Questions

    What is the recommended Tesamorelin dosage?

    The typical dose range for Tesamorelin is 1,000–2,000 mcg (1–2 mg) daily. It is usually administered Once daily subcutaneous injection. Always start with the lowest effective dose.

    How often should I take Tesamorelin?

    Once daily subcutaneous injection

    Does Tesamorelin need to be cycled?

    Yes, typical cycle length is 12-26 weeks in clinical trials; ongoing use common.

    What are Tesamorelin side effects?

    The FDA approval program gave tesamorelin a well-characterized side-effect profile, which is a significant advantage over non-approved GHRH analogs. **Common (>10% in Phase 3 trials)** - Injection site reactions (erythema, pruritus, pain at the site) are the most frequent adverse event (~22% of patients). They are usually mild and resolve with site rotation. - Arthralgia (joint aches), an IGF-1-mediated connective tissue effect, typically appears 4-8 weeks into dosing and then stabilizes. - Pain in the extremities relates to fluid shifts and peripheral tissue expansion. - Myalgia (mild muscle aches) also comes from IGF-1-mediated connective tissue changes. - Peripheral edema is dose-dependent, GH-mediated fluid retention; it is mild and usually resolves within weeks. **Uncommon (1-10%)** - Carpal tunnel symptoms come from fluid-shift-mediated peripheral compression and should prompt dose reduction or discontinuation. - Paresthesias (hand tingling) are an early sign of fluid retention. - Insulin resistance or raised fasting glucose can appear, since all GH-raising therapies impair glucose tolerance. The FDA label reports an intent-to-treat odds ratio of 3.3 (CI 1.4, 9.6) for reaching an HbA1c of 6.5% or more. - Rash and urticaria are hypersensitivity-spectrum reactions. **Important** - By week 26, 5% of treated patients had reached an HbA1c of 6.5% or more (hyperglycemia or new-onset diabetes), against 1% on placebo, so patients with diabetes or pre-diabetes need close monitoring. - Fluid retention is a concern with CHF: tesamorelin is contraindicated in patients with acute critical illness, heart failure or severe edema. - IGF-1 can rise above the reference range. Per the FDA label, 47% of patients had IGF-1 above 2 SDS and 36% above 3 SDS at 26 weeks, and 34% and 23% at 52 weeks. Tesamorelin carries no FDA boxed (black box) warning. **Contraindications per FDA label** - Disruption of the hypothalamic-pituitary axis (pituitary tumor removal, hypopituitarism, hypothalamic injury) - Active malignancy, as an absolute contraindication, because the GH/IGF-1 axis may accelerate tumor growth - Pregnancy - Pediatrics, where it has not been studied **What tesamorelin does not do** - It does not raise prolactin or cortisol, unlike GHRP-2/6 or hexarelin. - It does not cause the continuous GH elevation of CJC-1295-DAC. - Because the pulse pattern preserves physiologic regulation, it does not cause the acromegalic body-composition changes of chronic recombinant GH. - Unlike some older peptide injections, it does not cause injection-site lipodystrophy. **Monitoring requirements** Per the FDA label and standard clinical practice: - At baseline, check fasting glucose, IGF-1, HbA1c, a comprehensive metabolic panel and thyroid (TSH, free T4). - At weeks 4-8, check IGF-1 against the age-adjusted reference range, and reduce the dose or discontinue if it exceeds the ULN. - Quarterly on long-term therapy, check HbA1c, liver function, IGF-1 and fasting glucose. - Annually, reassess the need for continued therapy, since tesamorelin suppresses visceral fat without curing it. **Long-term safety framing** The Phase 3 and extension data cover ~2 years; beyond that, safety is extrapolated from the broader GH/IGF-1 literature. For adults on tesamorelin beyond 2 years, standard clinical practice is active surveillance for malignancy (general cancer screening appropriate for age and sex), periodic IGF-1 monitoring and glucose/HbA1c surveillance.

    Where can I buy Tesamorelin?

    Compare 5 listings from 3 vendors on our price comparison page, starting from $44.99.

    Free 2026 Peptide Cheat Sheet (PDF)

    38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

    Download Free